Molecular
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 2004-01-01
- Employees
- 167
- Market Cap
- $229.6M
- Introduction
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274 and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.
Clinical Trials
27
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (25 trials with phase data)• Click on a phase to view related trials
Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Conditions
- LeukemiaNewly DiagnosedMyeloidAcute
- Interventions
- Drug: MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1Drug: MP0533 with Obinutuzumab pretreatmentDrug: MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B in treatment naïve patientsDrug: MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 2-Arm ADrug: MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) + azacitidine + venetoclaxDrug: MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B relapsed/refractory AML
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Molecular Partners AG
- Target Recruit Count
- 249
- Registration Number
- NCT05673057
- Locations
- 🇫🇷
CHU Bordeaux, Bordeaux, France
🇫🇷AP-HP Hôpital Saint-Louis, Paris, France
🇫🇷IUCT Oncopole, Toulouse, France
First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors
- Conditions
- Advanced Malignant Solid Tumor
- Interventions
- Drug: MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q3w regimen)Drug: MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q1w regimen)
- First Posted Date
- 2021-10-28
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- Molecular Partners AG
- Target Recruit Count
- 46
- Registration Number
- NCT05098405
- Locations
- 🇫🇷
Centre Léon Bérard, Lyon, France
🇫🇷IUCT-O Institut Claudius Régaud, Toulouse, France
🇳🇱NKI-AvL, Amsterdam, Netherlands
Safety, Tolerability and PK of Ensovibep (MP0420 - a New Candidate With Potential for Treatment of COVID-19)
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2022-03-18
- Lead Sponsor
- Molecular Partners AG
- Target Recruit Count
- 53
- Registration Number
- NCT04870164
- Locations
- 🇬🇧
HMR, London, United Kingdom
Viral Clearance, PK and Tolerability of Ensovibep in COVID-19 Patients
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2021-09-08
- Lead Sponsor
- Molecular Partners AG
- Target Recruit Count
- 12
- Registration Number
- NCT04834856
- Locations
- 🇳🇱
Centre for Human Drug Research, Leiden, Netherlands
Study to Investigate the Safety, Blood Levels and Activity of MP0310 in Patients With Advanced Solid Tumors
- First Posted Date
- 2019-08-08
- Last Posted Date
- 2022-12-22
- Lead Sponsor
- Molecular Partners AG
- Target Recruit Count
- 38
- Registration Number
- NCT04049903
- Locations
- 🇫🇷
Centre Léon Bérard, Lyon, France
🇫🇷Institut Claudius Regaud; Institut Universitaire du Cancer Toulouse Oncopole (IUCT-O), Toulouse, France
🇫🇷Institut Gustave Roussy, Villejuif, France
- Prev
- 1
- 2
- Next